Adaptin Bio (APTN) Total Non-Current Liabilities (2025 - 2026)
Adaptin Bio (APTN) reported Total Non-Current Liabilities of $1.9 million for Q1 2026, up 246.28% year-over-year from $557471.0 in Q1 2025, and up 23.96% sequentially from $1.6 million in Q4 2025.
Adaptin Bio (APTN) Total Non-Current Liabilities (2025 - 2026) Analysis & Trends
Adaptin Bio has disclosed Total Non-Current Liabilities across 2 years of filings, most recently posting $1.9 million for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 246.28% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 246.28% YoY) and the FY2025 annual result came in at $1.6 million, changed N/A from the prior year.
- Total Non-Current Liabilities improved to $1.9 million in Q1 2026, from $1.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.9 million in Q1 2026 and bottomed at $557471.0 in Q1 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.93 Mn |
| Dec 31, 2025 | 1.56 Mn |
| Sep 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | 636,957.00 |
| Mar 31, 2025 | 557,471.00 |